Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?

The incidence of pancreatic ductal adenocarcinoma (PDAC) has been on the rise in recent years; however, its clinical diagnosis and treatment remain challenging. Although surgical resection remains the only chance for long-term patient survival, the likelihood of initial resectability is no higher th...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Chenqi, Tan, Guang, Zhang, Jie, Fan, Bin, Chen, Yunlong, Chen, Dan, Yang, Lili, Chen, Xiang, Duan, Qingzhu, Maimaiti, Feiliyan, Du, Jian, Lin, Zhikun, Gu, Jiangning, Luo, Haifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245892/
https://www.ncbi.nlm.nih.gov/pubmed/35785193
http://dx.doi.org/10.3389/fonc.2022.828223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9245892/
https://www.ncbi.nlm.nih.gov/pubmed/35785193
http://dx.doi.org/10.3389/fonc.2022.828223

Ejemplares similares